This six-episode podcast interview series is chaired by Dr. Richard Isaacson and includes information from the AAIC 2020 Virtual Conference. Dr. Isaacson interviews five expert faculty on the six agenda topics that will include how to best manage Alzheimer’s patients during the COVID-19 Pandemic and transitioning to telemedicine. The discussions will also cover clinical trial data, early diagnosis, imaging, and genetics in Alzheimer’s disease.
Neurologists, primary care physicians, nurses, pharmacists, PA’s, NP’s and other healthcare providers who care for patients with Alzheimer’s disease
Please click the link below each podcast episode to take you to your preferred streaming service
- Discuss strategies for virtual medical care during the COVID-19 pandemic for patients with Alzheimer’s disease.
- Analyze recent clinical trial data from the virtual AAIC 2020 program for therapeutic options to manage patients with Alzheimer’s disease.
- Understand the basis for biomarkers in diagnosis and monitoring disease progression in Alzheimer’s disease.
- Review current AD science and the role of genetics and mechanisms of synaptic dysfunction.
- Discuss advances in neuroimaging technology, including amyloid and tau imaging, MRI, and PET.
- Improve ability to recognize AD symptoms and develop individualized strategies for optimal patient care.
Richard S. Isaacson, MD
Associate Professor of Neurology
Weill Cornell Medicine
Director, Alzheimer’s Prevention Clinic
New York Presbyterian Hospital
New York, New York
Roberta Marongiu, Ph.D.
Assistant Professor of Neuroscience
Department of Neurological Surgery
Brain and Mind Research Institute
Weill Cornell Medicine
Marwan N. Sabbagh, MD, FAAN, CCRI
Camille and Larry Ruvo Endowed Chair for Brain Health
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Richard Isaacson, MD||Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me|
|Marc Agronin, MD
|Consultant/Advisor: Eli Lilly and Company
Speaker’s Bureau: Allergan
|Hollie Hristov, FNP||Nothing to disclose|
|Roberta Marongiu, PhD||Nothing to disclose|
|Juan Melendez, MD||Nothing to disclose|
|Marwan N. Sabbagh, MD||Consultant/Advisor: Alzheon; Athira; Biogen; Cortexyme; Danone; Eisai Co., Ltd.; Neurotrope; Regeneron Pharmaceuticals, Inc.; Roche-Genentech; Stage 2 Innovations; vTv Therapeutics
Ownership Interest: Brain Health, Inc.; NeuroReserve; Neurotau; Neurotrope; Optimal Cognitive Health Company; uMethod Health; Versanum Inc.
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, and Emma Boring hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 3.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 3.0 CNE Contact Hour, including 3.0 pharmacotherapeutic contact hour (Provider number P0491).
AcademicCME designates this continuing education activity for 3.0 CPE Contact Hour (0.30 CEU) of continuing pharmacy education credit (UAN # JA4008190-0000-20-014-H04-P).
This activity has been supported by an independent educational grant from Biogen.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Listen to each podcast series.
- Complete the Post-Activity Test Questions and Evaluation by clicking the link below.
- Learners who complete the Post-Activity Test Questions and the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
Please click here to download a set of resources pertaining to this activity.